NasdaqCM - Nasdaq Real Time Price USD

SciSparc Ltd. (SPRC)

0.3159
+0.0099
+(3.24%)
At close: May 16 at 4:00:00 PM EDT
0.3159
+0.00
+(0.35%)
Pre-Market: 7:03:16 AM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for SPRC

Recent News: SPRC

View More
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire 7 days ago
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire 7 days ago
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
GlobeNewswire 23 days ago
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea

SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
GlobeNewswire 2 months ago
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea

Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
GlobeNewswire 2 months ago
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
GlobeNewswire 2 months ago
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
GlobeNewswire 2 months ago
N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers

N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers
GlobeNewswire 2 months ago
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
GlobeNewswire 2 months ago
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
GlobeNewswire 3 months ago
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
GlobeNewswire 3 months ago
View More

Related Tickers

CMND Clearmind Medicine Inc.
0.9900
+2.06%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5229
-0.21%
 
DRMA Dermata Therapeutics, Inc.
0.7910
-0.38%
 
CDIO Cardio Diagnostics Holdings, Inc.
3.8400
-4.00%
 
PXMD PaxMedica, Inc.
0.0001
0.00%
 
ENSC Ensysce Biosciences, Inc.
2.3400
+9.35%
 
VRAX Virax Biolabs Group Limited
1.0800
+0.93%
 
RLMD Relmada Therapeutics, Inc.
0.4610
+11.51%
 
SLXN Silexion Therapeutics Corp
0.9160
-3.58%
 
IBO Impact BioMedical Inc.
0.5410
+5.27%